U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07184424) titled 'Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC' on Sept. 09.
Brief Summary: This study is a real-world, single-arm, observational study primarily collecting data on patients with hepatocellular carcinoma who experienced disease progression after receiving lenvatinib in combination with PD-1 inhibitors as part of routine clinical practice, and evaluating the efficacy of adding lenalidomide to their treatment regimen.
Study Start Date: May 24, 2023
Study Type: INTERVENTIONAL
Condition:
HCC - Hepatocellular Carcinoma
Intervention:
DRUG: lenalidomide
For patients with hepatocellu...